Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
By
Elizabeth Crawford, Malcolm Spicer / Email the Authors / “The Tan Sheet” Oct. 3, 2011, Vol. 19, No. 40
OTCs / Word Count: 1152 / Article # 05111003011
Executive Summary
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.